Friday 6 November 2026
Export ONC’s income statement to Excel — free account
BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
406.26
19.01
+4.91%
Follow ONC
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 7 | 7 | 7 |
+8 more TTM periods Free account |
| 18.40% | 14.66% | 12.42% | 7.46% | ||
| 10.46% | 8.47% | 7.13% | 4.07% | ||
ROIC |
85.21% | 60.22% | 46.03% | 36.03% | |
Return on Tangible Assets |
12.47% | 9.73% | 7.98% | 4.75% | |
Average Days of Receivables |
60.36 | 62.90 | 59.66 | 59.10 | |
Free Cash Flow per Share |
0.00 | 11.92 | 10.05 | 8.45 | |
Free Cash Flow |
1,449.25 | 1,330.19 | 1,114.61 | 921.74 | |
Capital Expenditures |
(140.96) | (153.87) | (170.22) | (205.84) | |
| Other line items | |||||
Cash ROIC |
11.66% | 11.93% | 10.60% | 9.34% | |
Accounts Receivable Turnover |
6.76 | 6.71 | 6.93 | 6.93 | |
Accounts Payable Turnover |
1.59 | 1.64 | 1.70 | 1.51 | |
Inventory Turnover |
1.05 | 1.10 | 1.14 | 1.21 | |
Average Days of Payables |
258.69 | 252.19 | 230.48 | 261.54 | |
Days of Inventory on Hand |
420.63 | 392.84 | 370.90 | 332.07 | |
Tax Rate |
(0.19) | (0.24) | (0.22) | (0.31) | |
Research and Development Expense of Revenue |
36.78% | 37.41% | 38.42% | 40.16% | |
Selling, General and Administrative Expense of Revenue |
34.77% | 36.43% | 37.94% | 38.96% | |
Share Based Compensation of Revenue |
7.83% | 8.57% | 9.39% | 9.56% | |
Interest Coverage |
— | 7.45 | 7.53 | 4.89 | |
Operating CF/Net income |
1.74 | 2.26 | 2.50 | 3.93 | |
Depreciation/Fixed assets |
0.11 | 0.09 | 0.09 | 0.09 | |
Capex/Depreciation |
(0.79) | (0.99) | (1.13) | (1.45) | |
Revenue per Share |
0.00 | 54.93 | 51.72 | 48.99 | |
Operating CF per Share |
0.00 | 13.30 | 11.58 | 10.34 | |
Capex per Share |
0.00 | (1.38) | (1.53) | (1.89) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026